Results 61 to 70 of about 1,591,450 (336)

Sequential Metastatic Breast Cancer Chemotherapy:Should the Median be the Message?

Frontiers in Public Health, 2013
Background: Counseling and anticipatory guidance of the expected course of treatment for women newly diagnosed with metastatic breast cancer (MBC) are difficult due to multiple factors influencing survival following metastatic breast cancer therapy.
Su Yon eJung, Margaret eRosenzweig
doaj   +1 more source

MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells [PDF]

, 2018
Mir-205 plays an important role in epithelial biogenesis and in mammary gland development but its role in cancer still remains controversial depending on the specific cellular context and target genes.
De Cola A., De Laurenzi V., Iezzi M., Lamolinara A., Lanuti P., Marchisio M., Rossi C., Todaro M.   +7 more
core   +1 more source

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

New England Journal of Medicine, 2022
METHODS We conducted a phase 3 trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. (Low expression of HER2 was defined as a score of 1+ on immunohistochemical [IHC] analysis or as an
S. Modi, W. Jacot, T. Yamashita, J. Sohn, M. Vidal, E. Tokunaga, J. Tsurutani, N. Ueno, A. Prat, Y. Chae, K. Lee, N. Niikura, Yeon-Hee Park, Bing-he Xu, Xiao-juan Wang, M. Gil-Gil, Wei Li, J. Pierga, S. Im, H. Moore, H. Rugo, R. Yerushalmi, F. Zagouri, A. Gombos, Sung-Bae Kim, Qiang Liu, T. Luo, C. Saura, P. Schmid, T. Sun, D. Gambhire, L. Yung, Yibin Wang, Jasmeet Singh, P. Vitazka, G. Meinhardt, N. Harbeck, D. Cameron   +37 more
semanticscholar   +1 more source

Multiple ETS family transcription factors bind mutant p53 via distinct interaction regions

FEBS Letters, EarlyView.
Mutant p53 gain‐of‐function is thought to be mediated by interaction with other transcription factors. We identify multiple ETS transcription factors that can bind mutant p53 and found that this interaction can be promoted by a PXXPP motif. ETS proteins that strongly bound mutant p53 were upregulated in ovarian cancer compared to ETS proteins that ...
Stephanie A. Metcalf, Nicholas F. Downing, Kaitlyn M. Mills, Samuel C. Metcalfe, Alexander E. Kritzer, Lindsey D. Mayo, Peter C. Hollenhorst   +6 more
wiley   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Occult Breast Carcinoma Presenting as Scalp Metastasis

Case Reports in Oncology, 2017
Breast cancer is the most common tumor among women, and approximately 6% of the patients have de novo metastatic breast cancer. Occult breast cancer accounts for only 0.1–0.8% of the cases and most commonly presents with axillary lymphadenopathy.
Ricardo L.B. Costa, Rubens B. Costa-Filho, Marilin Rosa, Brian J. Czerniecki   +3 more
doaj   +1 more source

Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cells [PDF]

, 2019
Metastatic competence of cancer cells is influenced by many factors including metabolic alterations and changes in mitochondrial biogenesis and protein homeostasis.
Daverey, Amita, Hayward, Stephen, Khalimonchuk, Oleh, Kidambi, Srivatsan, Levytskyy, Roman M., Narasimhan, Madhusudhanan, Ponte Viana, Martonio, Stanke, Kimberly M., Swenson, Samantha   +8 more
core   +1 more source

Burden of early, advanced and metastatic breast cancer in The Netherlands [PDF]

, 2018
BACKGROUND: The aim of this study was to estimate the total economic and health related burden of breast cancer in the Netherlands. METHODS: Data on incidence, prevalence, mortality and survival were extracted from the Dutch National Cancer Registry and ...
Dvortsin, E P, Jansman, F G A, Konings, I R, Menezes, G L, Postma, M J, Rozenbaum, M H, Vondeling, G T   +6 more
core   +2 more sources

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis. [PDF]

, 2019
ROR1 is a conserved oncoembryonic surface protein expressed in breast cancer. Here we report that ROR1 associates with cortactin in primary breast-cancer cells or in MCF7 transfected to express ROR1.
Briggs, Steven P, Hasan, Md Kamrul, Kipps, Thomas J, Lam, Sharon M, Parker, Barbara A, Shen, Zhouxin, Widhopf, George F, Zhang, Suping   +7 more
core   +1 more source